EA202192567A1 - METHODS FOR THE TREATMENT OF MUSCULAR DYSTROPHY USING CASIMERSENA - Google Patents

METHODS FOR THE TREATMENT OF MUSCULAR DYSTROPHY USING CASIMERSENA

Info

Publication number
EA202192567A1
EA202192567A1 EA202192567A EA202192567A EA202192567A1 EA 202192567 A1 EA202192567 A1 EA 202192567A1 EA 202192567 A EA202192567 A EA 202192567A EA 202192567 A EA202192567 A EA 202192567A EA 202192567 A1 EA202192567 A1 EA 202192567A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
muscular dystrophy
treatment
casimersena
provides
Prior art date
Application number
EA202192567A
Other languages
Russian (ru)
Inventor
Эдвард М. Кайе
Original Assignee
Сарепта Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сарепта Терапьютикс, Инк. filed Critical Сарепта Терапьютикс, Инк.
Priority claimed from PCT/US2020/024550 external-priority patent/WO2020198268A1/en
Publication of EA202192567A1 publication Critical patent/EA202192567A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Изобретение предусматривает, наряду с прочим, улучшенные композиции и способы лечения мышечной дистрофии. Например, настоящее изобретение предусматривает способы лечения пациентов с мышечной дистрофией Дюшенна, имеющих мутацию в гене DMD, которая поддается лечению посредством пропуска экзона 45, посредством введения эффективного количества касимерсена.The invention provides, among other things, improved compositions and methods for the treatment of muscular dystrophy. For example, the present invention provides methods for treating patients with Duchenne muscular dystrophy having a mutation in the DMD gene that is treatable by exon 45 skipping by administering an effective amount of casimersen.

EA202192567A 2019-09-19 2020-03-25 METHODS FOR THE TREATMENT OF MUSCULAR DYSTROPHY USING CASIMERSENA EA202192567A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962902518P 2019-09-19 2019-09-19
PCT/US2020/024550 WO2020198268A1 (en) 2019-03-28 2020-03-25 Methods for treating muscular dystrophy with casimersen

Publications (1)

Publication Number Publication Date
EA202192567A1 true EA202192567A1 (en) 2021-12-09

Family

ID=80631180

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192567A EA202192567A1 (en) 2019-09-19 2020-03-25 METHODS FOR THE TREATMENT OF MUSCULAR DYSTROPHY USING CASIMERSENA

Country Status (1)

Country Link
EA (1) EA202192567A1 (en)

Similar Documents

Publication Publication Date Title
EA201890811A1 (en) METHODS OF TREATMENT OF MUSCULAR DISTROPHIA
EA202092248A1 (en) SUBSTITUTED COMPOUNDS OF 4-AMINOISOINDOLINE-1,3-DIONE, THEIR COMPOSITIONS AND METHODS OF THEM TREATMENT
MA45811A (en) METHODS AND COMPOSITIONS OF TREATMENT OF DISEASE.
MX2022007968A (en) Gamma-hydroxybutyrate (ghb) dosing.
MX2021005348A (en) Pyridazinone compounds and uses thereof.
EA202190377A9 (en) CXCR4 INHIBITOR COMPOSITIONS AND METHODS FOR PREPARATION AND APPLICATION
EA202092086A1 (en) ARGINASE INHIBITORS
MX2020002038A (en) Methods for treating muscular dystrophy.
MX2021014350A (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith.
EA202192815A1 (en) AAV-VECTOR-MEDIATED LARGE MUTATION HOTSPOINT DELETION FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
MX2021012706A (en) Dihydroorotate dehydrogenase inhibitors.
MX2021014175A (en) Treatment of hair loss disorders with deuterated jak inhibitors.
EA202191519A1 (en) TREX1 MODULATORS
MX2021009521A (en) Dihydroorotate dehydrogenase inhibitors.
EA202192625A1 (en) PSEUDOKINASE TYK2 LIGANDS
MX2022001004A (en) Enzyme inhibitors.
BR112022005757A2 (en) Improved uricase and hyperuricemia treatment method using the same
MX2022001933A (en) Enzyme inhibitors.
MX2021011498A (en) Methods for treating muscular dystrophy with casimersen.
EA202193334A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING FXR AGONIST AND FIBRATE FOR USE IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE
MX2022000811A (en) Enzyme inhibitors.
EA202192567A1 (en) METHODS FOR THE TREATMENT OF MUSCULAR DYSTROPHY USING CASIMERSENA
EA202192047A1 (en) COMPOUNDS AND THEIR APPLICATIONS
EA202190226A1 (en) METHODS FOR TREATMENT OF HFpEF USING DAPAGLIFLOSIN AND COMPOSITIONS CONTAINING IT
MX2022012229A (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19.